ADXNAddex TherapeuticsADXN info
$0.09info0.26%24h
Global rank32122
Market cap$12.03M
Change 7d-4.77%
YTD Performance64.78%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Addex Therapeutics (ADXN) Stock Overview

    Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

    ADXN Stock Information

    Symbol
    ADXN
    Address
    Chemin des Mines, 9Geneva, 1202Switzerland
    Founded
    -
    Trading hours
    -
    Website
    https://www.addextherapeutics.com
    Country
    🇨🇭 Switzerland
    Phone Number
    41 22 884 1555

    Addex Therapeutics (ADXN) Price Chart

    -
    Value:-

    Addex Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.08950289290353053
    N/A
    Market Cap
    $12.03M
    N/A
    Shares Outstanding
    134.37M
    N/A
    Employees
    24.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org